Exagen stock analysis
Exagen (E08A) Stock Price & Analysis
E08A Stock Chart & Stats
- Day’s Range
- EUR 3.54 - EUR 3.54
- 52-Week Range
- EUR 2.26 - EUR 7.60
- Previous Close
- EUR 3.38
- Volume
- N/A
- Average Volume (3M)
- 4
- Market Cap
- EUR 88.36M
- Enterprise Value
- EUR 202.70M
- Total Cash (Recent Filing)
- EUR 28.09M
- Total Debt (Recent Filing)
- EUR 28.76M
- Price to Earnings (P/E)
- ―
- Beta
- 1.06
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- -0.17
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross Margins
Rapid revenue expansion combined with stable gross margins indicates meaningful demand and sound test-level economics. If Exagen sustains growth while increasing operating leverage, the existing revenue base can support improving profitability and strengthen the company’s position in autoimmune diagnostics over the next several quarters.
Growing AVISE Adoption
A growing installed base of AVISE tests and ordering physicians supports recurring clinical utilization and broader market penetration. Continued adoption can reinforce physician familiarity, expand testing volume, and improve the durability of Exagen’s autoimmune diagnostics platform beyond short-term quarterly fluctuations.
Pipeline And Platform Expansion
Launching a differentiated myositis panel and expanding Pharma Services broaden Exagen beyond its established AVISE offering. The planned faster turnaround and wider biomarker menu could create additional clinical utility, while the services business provides another avenue for revenue diversification and platform growth.
Bears Say
Persistent Unprofitability
Despite strong top-line growth, Exagen remains materially loss-making, showing that current scale has not yet produced sustainable earnings. Continued operating losses could constrain reinvestment and leave the company dependent on further growth, cost discipline, and operating leverage to reach its targeted adjusted EBITDA breakeven.
Negative Cash Generation
Ongoing negative operating and free cash flow means the business is not yet self-funding its operations. Although burn has improved versus earlier periods, continued cash consumption can require financing and increase dilution or refinancing risk if revenue growth and margin improvement do not progress as planned.
Reimbursement And Payer Uncertainty
Exagen’s testing revenue depends on reimbursement and payer access, making unresolved policy and coverage issues a durable execution risk. Potential generic-code rate pressure and prolonged negotiations with payers could reduce realized revenue per test or delay adoption, complicating the path to profitability.
E08A FAQ
What was Exagen’s price range in the past 12 months?
What is Exagen’s market cap?
When is Exagen’s upcoming earnings report date?
How were Exagen’s earnings last quarter?
Is Exagen overvalued?
Does Exagen pay dividends?
What is Exagen’s EPS estimate?
How many shares outstanding does Exagen have?
What happened to Exagen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Exagen?
What is the TipRanks Smart Score and how is it calculated?
Exagen Stock Smart Score
Company Description
Exagen
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- John Aballi
- Employees
- 216
- Website
- www.exagen.com
- Address
- 1261 Liberty Way, Vista, CA, 92081, US
Exagen (E08A) Earnings & Revenues
E08A Company Deck
E08A Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with record quarterly revenue, double-digit year-to-date revenue growth, improving adjusted EBITDA, rising ASP, expanding commercial productivity, strong Pharma Services growth, balance sheet strengthening and meaningful progress toward the myositis launch. The principal challenges were modest third-quarter volume growth, normal seasonal effects, continued adjusted EBITDA losses, uncertain PAMA implementation and no update on the AVISE CTD LCD. Highlights significantly outweighed lowlights.
View all DE:E08A earnings summariesE08A Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |











